Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.1.4.1 (
phosphodiesterase
)
18,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In rabbit renal cortical collecting tubule (CCT), perfused in vitro at 38 degrees C, ATP in concentrations of 10(-7) M and greater inhibits arginine vasopressin (AVP)-stimulated osmotic water permeability (Pf). The P1-purinergic receptor antagonist 8-phenyltheophylline did not attenuate the inhibitory action of ATP, and the poorly hydrolyzable ATP analogue, 5'-adenylylimidodiphosphate (AMP-PNP), mimicked the effect of ATP, arguing against an effect of ATP on a P1 receptor or the "P site."
Purinergic receptor
agonists inhibited AVP-stimulated Pf with the following rank order efficacy: ATP = ADP = UTP = AMP-PNP = alpha, beta-methylene-ATP > 2-methylthio-ATP >> AMP > adenosine, consistent with the pharmacology of a "nucleotide" receptor subtype. Pertussis toxin pretreatment attenuated the action of 10(-5) and 10(-6) MATP; however, 10(-4) MATP failed to inhibit the hydrosmotic action of forskolin or 8-bromoadenosine 3',5'-cyclic monophosphate. Pretreatment with the
phosphodiesterase
inhibitor RO20-1724 or indomethacin did not inhibit the action of ATP. Staurosporin and 3,4,5-trimethoxybenzoic acid 8-(diethylamino)octyl ester significantly attenuated the inhibition of Pf by lower concentrations of ATP. These data suggest that ATP activates nucleotide receptors on the CCT, mobilizing intracellular Ca2+, which inhibits the hydrosmotic action of AVP.
...
PMID:ATP inhibits the hydrosmotic effect of AVP in rabbit CCT: evidence for a nucleotide P2u receptor. 806 90
Serotonin (5HT) and ATP are simultaneously released from activated platelets at the site of vascular injury and are hypothesized to play a significant role in hemostasis. Our laboratory investigated the modulation of vascular contraction of arterial ring segments by 5HT plus ATP as a model of the potential regulation of localized vascular tone by platelet releasates in regions of arterial damage. This study expands our focus on how these two vasoactive components, released from platelet dense granules, regulate vascular tone. 5HT- and 5HT analog-induced vasoconstrictions were measured in the presence or absence of ATP and ATP analogs with intact or deendothelialized rat pulmonary arterial ring segments suspended in organ baths. The possible presence of 5HT2 and 5HT1A receptor types in the rat pulmonary artery was demonstrated by vasoconstrictions induced by 5HT and (+)-8-hydroxy-2-(di-N-propylamino) tetralin hydrobromide (DPAT). The DPAT response was only 30%-50% of that induced by comparable concentrations of 5HT. The 5HT-induced contraction was inhibited by the 5HT2 antagonist, ketanserin. ATP equally relaxed 5HT and DPAT contracted tissue while the P2X agonist, alphabeta-methylene ATP, increased the contracted state of DPAT-treated arteries to a significantly greater extent than observed with 5HT. The P2y agonist, 3'-O-(4-benzoyl)benzoyl ATP (BzATP), the P2X agonist betagamma-methylene ATP, and ATP all relaxed 5HT-induced contractions to similar levels under a number of physiological conditions. The final level of 5HT-induced tissue contraction was the same whether ATP was added prior to, after, or simultaneously with 5HT. ATP and the
phosphodiesterase
inhibitor, theophylline, inhibited 5HT-induced vasoconstriction in an additive fashion. The ATP effects were endothelium dependent, while the inhibition by theophylline was not. The distribution of 5HT and
ATP receptor
types, as indicated by these and numerous other studies, appears to vary within different regions of the cardiovascular system. Extracellular ATP can synergistically enhance or inhibit 5HT-contracted blood vessels differentially at localized regions, which would significantly impact on localized vascular tone, and this in turn may modulate hemostasis and thrombosis.
...
PMID:ATP modification of serotonin-induced contraction of the rat pulmonary artery. 908 56
Follicular Xenopus oocytes possess a novel receptor where both adenosine and ATP activate a cAMP-dependent, nonrectifying K+-current. Five compounds, alpha,beta-methylene ATP (alpha, beta-meATP), 8-(p-sulfophenyl)theophylline (8-SPT), theophylline, 2, 2'-pyridylisatogen tosylate (PIT) and suramin, were tested as antagonists of adenosine- and ATP-activated K+-currents. The descending order of activity (pIC50 values) against adenosine responses was: alpha,beta-meATP (6.72) = 8-SPT (6.68) > theophylline (5.32) > PIT (4.58), whereas suramin was relatively inactive. The blocking actions of alpha,beta-meATP and alkylxanthine compounds were reversible with washout, whereas blockade by PIT was irreversible. These antagonists showed similar blocking activity against ATP responses, except for PIT which was more effective at ATP responses than at adenosine responses. The selectivity of antagonists was tested against cAMP-dependent K+-currents evoked by forskolin and follicle-stimulating hormone (FSH). 8-SPT and theophylline did not inhibit but instead augmented forskolin and FSH responses; this augmentation may be caused by inhibition of
phosphodiesterase
activity inside follicle cells. On the other hand, alpha,beta-MeATP and PIT inhibited forskolin and FSH responses; both compounds apparently are nonselective antagonists. Thus, only alkylxanthine derivatives (8-SPT and theophylline) were selective antagonists of the novel adenosine/
ATP receptor
in Xenopus oocytes, whereas alpha,beta-meATP and PIT were nonselective in their blocking actions and suramin was relatively inactive.
...
PMID:Antagonism of an adenosine/ATP receptor in follicular Xenopus oocytes. 961 1